SubsidieMeestersBreaching the protective cancer stroma with radiotherapy-responsive liposomes
This project aims to enhance liposomal drug delivery in pancreatic cancer by integrating radiocatalytic nanomaterials for controlled drug release and improved tissue permeability through radiotherapy.
Projectdetails
Introduction
Liposomes have been the most successful type of nanomedicine for cancer patients, playing a leading role in improving the tolerability of chemotherapeutics. However, to advance the success of liposomal drug delivery and cancer treatment, new approaches to physically trigger drug release in cancer tissues and increase the permeability of the protective cancer stroma are needed. This project will investigate whether radiocatalytic nanomaterials can be integrated in liposomes for spatiotemporal-controlled drug release, the alleviation of cancer desmoplasia, and improved efficacy of co-encapsulated drugs.
Liposome Composition
Liposomes will be composed of oxidation-susceptible phospholipids that encapsulate hydrophilic drugs in their aqueous core. Radiation-absorbing nanomaterials will be included in the liposomes to produce high levels of reactive oxygen species when activated by X-rays.
Mechanism of Action
This will oxidize the liposomes and facilitate the release of the encapsulated drugs. Simultaneously, the cytotoxicity of the oxidants is expected to reduce the high cell densities in the tumor periphery, enabling the therapeutics to deeply permeate the cancer tissues following their release.
Focus on Pancreatic Cancer
This customizable strategy will be developed in the context of pancreatic cancer, a chemoresistant form of cancer with poor survival rates.
Multidisciplinary Approach
This project develops a multidisciplinary approach to investigate:
- The physicochemical mechanisms of radiotherapy-induced drug release.
- Adaptive optics microscopy to study tissue permeability in 3D cultures of desmoplastic pancreatic cancer.
- Multimodal in vivo imaging to uncover the therapeutic potential and mechanisms.
Novel Concept
Radiotherapy-controlled drug release from liposomes is a ground-breaking novel concept, and its capacity to increase cancer tissue permeability has never before been demonstrated. When successful, new avenues for controlled liposomal drug delivery will emerge that can significantly advance the standard-of-care for many cancer patients.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.942.158 |
| Totale projectbegroting | € 1.942.158 |
Tijdlijn
| Startdatum | 1-4-2023 |
| Einddatum | 31-3-2028 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Mechano-modulation of tumor microenvironment with mechanotherapeutics and sonopermeation to optimize nano-immunotherapyThis project aims to enhance drug delivery and treatment efficacy in desmoplastic tumors by synergistically combining mechanotherapeutics and ultrasound sonopermeation, supported by computational modeling. | ERC Starting... | € 1.500.000 | 2023 | Details |
Engineering lipid nanoparticles to target and escape the endosome, deliver their cargo and perform better as breast cancer therapiesThis project aims to enhance LNP-mRNA nanomedicine efficacy for advanced breast cancer by improving endosomal escape through nanoscale engineering and tailored formulations. | ERC Starting... | € 1.844.248 | 2024 | Details |
Remotely actuated re-shaped nanocarriers for tumour targetingDeveloping remotely actuated, anisotropic metal/polymer hybrid nanoparticles for targeted drug delivery in cancer to enhance therapeutic efficacy and minimize side effects. | ERC Proof of... | € 150.000 | 2022 | Details |
Nanoscintillators to potentiate brain cancer radiotherapy: from physics to preclinical trialsThis project aims to enhance radiation therapy for glioblastoma by studying nanoscintillators' effects on tumor tissues, improving treatment efficacy while minimizing damage to healthy cells. | ERC Starting... | € 1.948.125 | 2024 | Details |
Capturing tumoral drug metabolism by Cells In the Tissue Environment using spatial pharmacometabolomicsThe CITE project aims to develop innovative analytical technologies to study intratumoral drug metabolism in pancreatic cancer, enhancing understanding of treatment resistance mechanisms. | ERC Starting... | € 2.481.640 | 2024 | Details |
Mechano-modulation of tumor microenvironment with mechanotherapeutics and sonopermeation to optimize nano-immunotherapy
This project aims to enhance drug delivery and treatment efficacy in desmoplastic tumors by synergistically combining mechanotherapeutics and ultrasound sonopermeation, supported by computational modeling.
Engineering lipid nanoparticles to target and escape the endosome, deliver their cargo and perform better as breast cancer therapies
This project aims to enhance LNP-mRNA nanomedicine efficacy for advanced breast cancer by improving endosomal escape through nanoscale engineering and tailored formulations.
Remotely actuated re-shaped nanocarriers for tumour targeting
Developing remotely actuated, anisotropic metal/polymer hybrid nanoparticles for targeted drug delivery in cancer to enhance therapeutic efficacy and minimize side effects.
Nanoscintillators to potentiate brain cancer radiotherapy: from physics to preclinical trials
This project aims to enhance radiation therapy for glioblastoma by studying nanoscintillators' effects on tumor tissues, improving treatment efficacy while minimizing damage to healthy cells.
Capturing tumoral drug metabolism by Cells In the Tissue Environment using spatial pharmacometabolomics
The CITE project aims to develop innovative analytical technologies to study intratumoral drug metabolism in pancreatic cancer, enhancing understanding of treatment resistance mechanisms.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography ApproachPERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects. | EIC Pathfinder | € 2.740.675 | 2023 | Details |
Specific Conjugation of Antibodies to Lipid Photo-peroxidised cancer tissues for their immunogenic ELiminationSCALPEL aims to revolutionize cancer treatment by using photodynamic therapy to destroy tumors while marking surviving cells for immune system targeting, potentially offering a curative photoimmunotherapy. | EIC Pathfinder | € 4.554.301 | 2025 | Details |
SUPRAMOLECULAR AGENTS AS RADIOTHERANOSTIC DRUGSSMARTdrugs aims to revolutionize cancer treatment by developing supramolecular radiotheranostics that integrate diagnostics and therapy for targeted drug delivery. | EIC Pathfinder | € 2.135.087 | 2024 | Details |
Functional chemical reprogramming of cancer cells to induce antitumor immunityThe RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments. | EIC Pathfinder | € 2.966.695 | 2024 | Details |
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy. | EIC Pathfinder | € 5.972.875 | 2024 | Details |
2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach
PERSEUS aims to develop a novel nanotechnology-based cancer therapy that activates under CT imaging to treat deep-seated, drug-resistant tumors with minimal side effects.
Specific Conjugation of Antibodies to Lipid Photo-peroxidised cancer tissues for their immunogenic ELimination
SCALPEL aims to revolutionize cancer treatment by using photodynamic therapy to destroy tumors while marking surviving cells for immune system targeting, potentially offering a curative photoimmunotherapy.
SUPRAMOLECULAR AGENTS AS RADIOTHERANOSTIC DRUGS
SMARTdrugs aims to revolutionize cancer treatment by developing supramolecular radiotheranostics that integrate diagnostics and therapy for targeted drug delivery.
Functional chemical reprogramming of cancer cells to induce antitumor immunity
The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.
NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.